Published in Eur Heart J on January 19, 2010
Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI) | NCT00091637
Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation (2012) 1.03
Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One (2011) 1.03
Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol (2011) 1.01
Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care (2010) 0.90
Mannose-binding lectin and the balance between immune protection and complication. Expert Rev Anti Infect Ther (2011) 0.89
Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. Clin Exp Immunol (2013) 0.83
MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans. Int J Cardiol (2011) 0.82
Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model. Am J Pathol (2014) 0.82
Mannan-binding lectin in cardiovascular disease. Biomed Res Int (2014) 0.81
If there is an evolutionary selection pressure for the high frequency of MBL2 polymorphisms, what is it? Clin Exp Immunol (2014) 0.79
Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction. Biomed Res Int (2013) 0.79
Complement activation and cardiac surgery: a novel target for improving outcomes. Anesth Analg (2012) 0.78
Mannose-binding lectin-the forgotten molecule? Nat Med (2011) 0.78
Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study. Arthritis Res Ther (2014) 0.77
Genetically Determined MBL Deficiency Is Associated with Protection against Chronic Cardiomyopathy in Chagas Disease. PLoS Negl Trop Dis (2016) 0.77
Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial. BMC Nephrol (2012) 0.77
Perioperative mannan-binding lectin (MBL) patterns in cardiac surgery may correlate with the clinical outcomes in MBL deficient patients. Ann Thorac Surg (2010) 0.75
Mannose-binding lectin: an ancient molecule with new implications in myocardial infarction. Eur Heart J (2010) 0.75
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Pathophysiology of coronary artery disease. Circulation (2005) 6.65
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med (2004) 6.55
Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med (2010) 5.43
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol (2008) 3.35
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J (2006) 3.14
Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulanttherapy. EuroIntervention (2009) 2.74
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation (2008) 2.59
Raised cardiac troponins. BMJ (2004) 2.51
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med (2007) 2.14
Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J (2007) 2.06
Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. EuroIntervention (2009) 1.94
Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA (2007) 1.93
Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med (2003) 1.81
Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes (2010) 1.76
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol (2003) 1.75
Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). J Am Coll Cardiol (2013) 1.70
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol (2006) 1.64
Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg (2003) 1.64
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation (2003) 1.63
Academic health leadership: looking to the future. Proceedings of a workshop held at the Canadian Institute of Academic Medicine meeting Québec, Que., Canada, Apr. 25 and 26, 2003. Clin Invest Med (2003) 1.61
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J (2006) 1.59
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J (2004) 1.58
Physical activity in patients with stable coronary heart disease: an international perspective. Eur Heart J (2013) 1.53
Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. JACC Cardiovasc Imaging (2010) 1.47
Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. J Am Coll Cardiol (2011) 1.45
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv (2010) 1.45
Coronary artery disease progression late after successful stent implantation. J Am Coll Cardiol (2012) 1.44
Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation (2008) 1.39
A first-in-man study of percutaneous myocardial cryotreatment in nonrevascularizable patients with refractory angina. Catheter Cardiovasc Interv (2009) 1.38
The pre-hospital fibrinolysis experience in Europe and North America and implications for wider dissemination. JACC Cardiovasc Interv (2011) 1.38
Should cities hosting mass gatherings invest in public health surveillance and planning? Reflections from a decade of mass gatherings in Sydney, Australia. BMC Public Health (2009) 1.23
Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J (2006) 1.19
Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol (2003) 1.18
Predictors of early readmission or death in elderly patients with heart failure. Am Heart J (2010) 1.18
Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms. Arterioscler Thromb Vasc Biol (2003) 1.16
Limited diagnostic yield of non-invasive coronary angiography by 16-slice multi-detector spiral computed tomography in routine patients referred for evaluation of coronary artery disease. Eur Heart J (2005) 1.13
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol (2013) 1.11
Cell targeting by a generic receptor-targeted polymer nanocontainer platform. J Control Release (2005) 1.11
Sensible guidelines for the conduct of large randomized trials. Clin Trials (2008) 1.07
Comparative outcome one year after formal cardiac rehabilitation: the effects of a randomized intervention to improve exercise adherence. Eur J Cardiovasc Prev Rehabil (2008) 1.05
Outbreaks of pandemic (H1N1) 2009 and seasonal influenza A (H3N2) on cruise ship. Emerg Infect Dis (2010) 1.04
Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol (2005) 1.03
Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol (2006) 1.02
Large streamlined trials in cardiovascular disease. Eur Heart J (2014) 1.01
Prognostic significance of newly acquired bundle branch block after aortic valve replacement. Am J Cardiol (2004) 1.01
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J (2006) 0.98
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction. Can J Cardiol (2011) 0.98
Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. Am Heart J (2006) 0.97
Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail (2012) 0.95
Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J (2006) 0.94
Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. Am Heart J (2010) 0.94
A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. Int J Cardiol (2004) 0.93
Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. J Am Coll Cardiol (2003) 0.91
Assessment of activity status and survival according to the Canadian Cardiovascular Society angina classification. Can J Cardiol (2009) 0.91
Progression of coronary artery disease during long-term follow-up of the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II). Clin Cardiol (2010) 0.91
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. J Thromb Thrombolysis (2012) 0.90
Right atrial pacing impairs cardiac function during resynchronization therapy: acute effects of DDD pacing compared to VDD pacing. J Am Coll Cardiol (2005) 0.90
A letter from CMAJ's editorial board to the CMA. CMAJ (2002) 0.90
Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study. Eur Heart J (2007) 0.89
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J (2003) 0.89
Rollator use adversely impacts on assessment of gait and mobility during geriatric rehabilitation. J Rehabil Med (2011) 0.89
Pseudoaneurysm of the superficial femoral artery associated with osteochondroma--a case report. Vasc Endovascular Surg (2005) 0.88
Influenza outbreak during Sydney World Youth Day 2008: the utility of laboratory testing and case definitions on mass gathering outbreak containment. PLoS One (2009) 0.88
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart (2006) 0.88